EUVIMEDEUVIMED entdecken
Open Access

Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH

Zhinous Shahidzadeh Yazdi iD, Elizabeth A Streeten, Hilary B Whitlatch, May E Montasser, Amber L Beitelshees, Simeon I Taylor iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Zhinous Shahidzadeh Yazdi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Parathyroid Hormone, Vitamin D Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Office of Dietary Supplements.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Canagliflozin has been reported to increase the risk of bone fracture—possibly mediated by decreasing 1,25-dihydroxyvitamin D (1,25(OH)2D) and increasing parathyroid hormone (PTH).

Objective

This work investigated whether baseline vitamin D (VitD) deficiency renders individuals vulnerable to this adverse effect and whether VitD3 supplementation is protective.

Methods

This community-based, outpatient study had a paired design comparing individual participants before and after VitD3 supplementation. Eleven VitD-deficient (25-hydroxyvitamin D [25(OH)D] ≤ 20 ng/mL) individuals were recruited from the Amish population in Lancaster, Pennsylvania. Participants underwent 2 canagliflozin challenge protocols (300 mg daily for 5 days): the first before and the second after VitD3 supplementation. In the VitD3 supplementation protocol, participants received VitD3 supplementation (50 000 IU once or twice a week depending on body mass index for 4-6 weeks) to achieve 25(OH)D of 30 ng/mL or greater. Two coprimary end points were identified: effects of VitD3 supplementation on canagliflozin-induced changes in 1,25(OH)2D and PTH. Secondary end points included effects of VitD3 supplementation on baseline levels of VitD metabolites and PTH.

Results

VitD3 supplementation increased mean 25(OH)D from 16.5 ± 1.6 to 44.3 ± 5.5 ng/mL (P = .0006) and 24,25-dihydroxyvitamin D (24,25(OH)2D) from 1.0 ± 0.1 to 4.3 ± 0.6 ng/mL (P = .0002). Mean 1,25(OH)2D and PTH were unchanged. VitD3 supplementation decreased the magnitude of canagliflozin-induced changes in 1,25(OH)2D (from −31.3%±4.7% to −9.3%±8.3%; P = .04) and PTH (from +36.2%±6.2% to +9.7%±3.7%; P = .005).

Conclusion

VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parathyroid HormoneVitamin D DeficiencyHumansCanagliflozinVitamin DVitaminsErgocalciferolsDietary Supplements

Stichwörter der Autor:innen

SGLT2 inhibitorand side effectbiomarkerbonevitamin D

Substanzen

1,25-dihydroxyvitamin DParathyroid HormoneCanagliflozinVitamin DVitaminsErgocalciferols

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

ORCID-Profile: Zhinous Shahidzadeh Yazdi, Simeon I Taylor

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health Office of Dietary Supplements

Zitieren

APA

Shahidzadeh Yazdi, Z., Streeten, E. A., Whitlatch, H. B., Montasser, M. E., Beitelshees, A. L., & Taylor, S. I. (2024). Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad554

Vancouver

Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, Taylor SI. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad554

BibTeX
@article{ShahidzadehYazdi2024,
  author = {Shahidzadeh Yazdi, Zhinous and Streeten, Elizabeth A and Whitlatch, Hilary B and Montasser, May E and Beitelshees, Amber L and Taylor, Simeon I},
  title = {Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad554}
}
Kostenlos starten →